HU217439B - Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények Download PDFInfo
- Publication number
- HU217439B HU217439B HU9401443A HU9401443A HU217439B HU 217439 B HU217439 B HU 217439B HU 9401443 A HU9401443 A HU 9401443A HU 9401443 A HU9401443 A HU 9401443A HU 217439 B HU217439 B HU 217439B
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- group
- bile acid
- hydrogen
- compound
- Prior art date
Links
- 0 CC(CCC(N)=O)C(CC1)[C@@](C)([C@@](*)C2)C1(C)[C@@]1[C@]2[C@@](C)(CC[C@@](*)C2)[C@]2C[C@]1* Chemical compound CC(CCC(N)=O)C(CC1)[C@@](C)([C@@](*)C2)C1(C)[C@@]1[C@]2[C@@](C)(CC[C@@](*)C2)[C@]2C[C@]1* 0.000 description 2
- RQZZNEXGHJQFJH-RGULEQPZSA-N CC(CCC(N)=O)C(CC[C@H]1[C@@H]([C@H](C2)[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@]3(C)O)[C@@]1(C)[C@H]2O Chemical compound CC(CCC(N)=O)C(CC[C@H]1[C@@H]([C@H](C2)[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@]3(C)O)[C@@]1(C)[C@H]2O RQZZNEXGHJQFJH-RGULEQPZSA-N 0.000 description 1
- IJFXHKFVRJVZLS-BOKCDFKGSA-N CC(CCC(Nc1n[nH]nn1)=O)C(CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C)C3)[C@@H]3C3)[C@H]1[C@@H]2[C@@]3(C)O Chemical compound CC(CCC(Nc1n[nH]nn1)=O)C(CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C)C3)[C@@H]3C3)[C@H]1[C@@H]2[C@@]3(C)O IJFXHKFVRJVZLS-BOKCDFKGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4315368 | 1993-05-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU9401443D0 HU9401443D0 (en) | 1994-08-29 |
| HUT67390A HUT67390A (en) | 1995-04-28 |
| HU217439B true HU217439B (hu) | 2000-01-28 |
Family
ID=6487579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9401443A HU217439B (hu) | 1993-05-08 | 1994-05-06 | Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5466815A (OSRAM) |
| EP (1) | EP0624596B1 (OSRAM) |
| JP (1) | JP3476157B2 (OSRAM) |
| KR (1) | KR100333149B1 (OSRAM) |
| AT (1) | ATE163938T1 (OSRAM) |
| AU (1) | AU666440B2 (OSRAM) |
| CA (1) | CA2123048C (OSRAM) |
| CY (1) | CY2119B1 (OSRAM) |
| CZ (1) | CZ289515B6 (OSRAM) |
| DE (1) | DE59405410D1 (OSRAM) |
| DK (1) | DK0624596T3 (OSRAM) |
| ES (1) | ES2115096T3 (OSRAM) |
| FI (1) | FI942075A7 (OSRAM) |
| GR (1) | GR3026496T3 (OSRAM) |
| HU (1) | HU217439B (OSRAM) |
| IL (1) | IL109581A (OSRAM) |
| NO (1) | NO304795B1 (OSRAM) |
| NZ (1) | NZ260469A (OSRAM) |
| TW (1) | TW289757B (OSRAM) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0624593A3 (de) * | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| TW289020B (OSRAM) * | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| US6323190B1 (en) | 1998-07-31 | 2001-11-27 | The Univeristy Of Georgia Research Foundation, Inc. | Estrogen mimetics lacking reproductive tract effects |
| CA2372493A1 (en) | 1999-04-30 | 2000-11-09 | Arch Development Corporation | Steroid derivatives |
| US7086134B2 (en) * | 2000-08-07 | 2006-08-08 | Shipley Company, L.L.C. | Alignment apparatus and method for aligning stacked devices |
| JP2005508281A (ja) * | 2001-02-08 | 2005-03-31 | ザ ユニバーシティー オブ シカゴ | ステロイド誘導体 |
| US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1392713B1 (en) * | 2001-05-03 | 2007-10-17 | The University of Chicago | Liver x receptor agonists |
| US7078396B2 (en) * | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
| US6816317B2 (en) * | 2002-01-31 | 2004-11-09 | Lightel Technologies Inc. | Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same |
| WO2003086303A2 (en) * | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| EP2289560B1 (en) * | 2004-07-08 | 2015-04-22 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| US7960439B1 (en) | 2006-06-12 | 2011-06-14 | Iowa State University Research Foundation, Inc. | Environmentally sensitive foldable oligomers |
| EP2459581A4 (en) * | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| JP5889321B2 (ja) | 2010-11-04 | 2016-03-22 | アルビレオ アクチエボラグ | 肝疾患の処置用のｉｂａｔ阻害剤 |
| WO2012064267A1 (en) | 2010-11-08 | 2012-05-18 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| EP3215179A4 (en) | 2014-11-06 | 2018-07-25 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| JP2017535570A (ja) * | 2014-11-26 | 2017-11-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| MX2017010376A (es) * | 2015-02-11 | 2017-12-20 | Enanta Pharm Inc | Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos. |
| WO2016161003A1 (en) | 2015-03-31 | 2016-10-06 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN111116699B (zh) * | 2015-04-28 | 2023-02-28 | 江苏豪森药业集团有限公司 | 胆酸衍生物及其制备方法和医药用途 |
| CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| EP3413878B1 (en) | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| KR102499441B1 (ko) | 2016-11-29 | 2023-02-13 | 이난타 파마슈티칼스, 인코포레이티드 | 술포닐우레아 담즙산 유도체의 제조 방법 |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| US10676500B2 (en) | 2017-04-07 | 2020-06-09 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| CN110996915B (zh) | 2017-08-09 | 2023-10-03 | 阿尔比里奥公司 | 考来烯胺丸粒、口服考来烯胺制剂及其用途 |
| EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| WO2019245448A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3911331A4 (en) * | 2019-01-14 | 2023-01-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF |
| EP3921027B1 (en) | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| RS63899B1 (sr) | 2019-02-06 | 2023-02-28 | Albireo Ab | Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| JP7044948B1 (ja) * | 2019-03-19 | 2022-03-30 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | 疎水性分析物のｉｎ ｖｉｔｒｏ診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
| TWI867107B (zh) | 2019-12-04 | 2024-12-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| TWI865673B (zh) | 2019-12-04 | 2024-12-11 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| MX2022006731A (es) | 2019-12-04 | 2022-06-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar. |
| TWI871392B (zh) | 2019-12-04 | 2025-02-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| KR20230117393A (ko) | 2020-12-04 | 2023-08-08 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| JP2025516153A (ja) | 2022-04-22 | 2025-05-27 | アルビレオ・アクチボラグ | Ａｓｂｔ阻害剤の皮下投与 |
| US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| US20250368678A1 (en) * | 2022-06-09 | 2025-12-04 | Shandong Luye Pharmaceutical Co., Ltd. | 19-nor-c3,3-disubstituted c21-azacyclo-substituted steroid and method for using same |
| JP2025521736A (ja) | 2022-07-05 | 2025-07-10 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2024121434A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2025119319A1 (zh) * | 2023-12-08 | 2025-06-12 | 山东绿叶制药有限公司 | 一种gabaa受体调节剂的晶型及其制备方法和应用 |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| FI106800B (fi) * | 1990-12-06 | 2001-04-12 | Hoechst Ag | Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi |
-
1993
- 1993-11-23 TW TW082109825A patent/TW289757B/zh active
-
1994
- 1994-05-02 DE DE59405410T patent/DE59405410D1/de not_active Expired - Lifetime
- 1994-05-02 DK DK94106848T patent/DK0624596T3/da active
- 1994-05-02 EP EP94106848A patent/EP0624596B1/de not_active Expired - Lifetime
- 1994-05-02 ES ES94106848T patent/ES2115096T3/es not_active Expired - Lifetime
- 1994-05-02 AT AT94106848T patent/ATE163938T1/de not_active IP Right Cessation
- 1994-05-05 FI FI942075A patent/FI942075A7/fi unknown
- 1994-05-05 US US08/238,741 patent/US5466815A/en not_active Expired - Lifetime
- 1994-05-06 IL IL109581A patent/IL109581A/en not_active IP Right Cessation
- 1994-05-06 NO NO934800A patent/NO304795B1/no not_active IP Right Cessation
- 1994-05-06 HU HU9401443A patent/HU217439B/hu not_active IP Right Cessation
- 1994-05-06 CA CA002123048A patent/CA2123048C/en not_active Expired - Fee Related
- 1994-05-06 CZ CZ19941135A patent/CZ289515B6/cs not_active IP Right Cessation
- 1994-05-06 AU AU61947/94A patent/AU666440B2/en not_active Ceased
- 1994-05-06 JP JP09442494A patent/JP3476157B2/ja not_active Expired - Fee Related
- 1994-05-06 NZ NZ260469A patent/NZ260469A/en unknown
- 1994-05-07 KR KR1019940009971A patent/KR100333149B1/ko not_active Expired - Fee Related
-
1998
- 1998-04-03 GR GR980400679T patent/GR3026496T3/el unknown
- 1998-09-29 CY CY9800037A patent/CY2119B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ260469A (en) | 1995-03-28 |
| US5466815A (en) | 1995-11-14 |
| CA2123048C (en) | 2005-11-29 |
| TW289757B (OSRAM) | 1996-11-01 |
| ES2115096T3 (es) | 1998-06-16 |
| HU9401443D0 (en) | 1994-08-29 |
| KR100333149B1 (ko) | 2002-09-19 |
| IL109581A0 (en) | 1994-08-26 |
| NO941677L (no) | 1994-11-09 |
| CZ113594A3 (en) | 1994-12-15 |
| CY2119B1 (en) | 2002-04-26 |
| DE59405410D1 (de) | 1998-04-16 |
| FI942075A0 (fi) | 1994-05-05 |
| JP3476157B2 (ja) | 2003-12-10 |
| CA2123048A1 (en) | 1994-11-09 |
| FI942075L (fi) | 1994-11-09 |
| AU666440B2 (en) | 1996-02-08 |
| AU6194794A (en) | 1994-11-10 |
| HUT67390A (en) | 1995-04-28 |
| EP0624596A2 (de) | 1994-11-17 |
| IL109581A (en) | 1998-03-10 |
| EP0624596A3 (de) | 1995-06-07 |
| NO941677D0 (no) | 1994-05-06 |
| JPH06329695A (ja) | 1994-11-29 |
| EP0624596B1 (de) | 1998-03-11 |
| DK0624596T3 (da) | 1998-10-07 |
| ATE163938T1 (de) | 1998-03-15 |
| FI942075A7 (fi) | 1994-11-09 |
| GR3026496T3 (en) | 1998-07-31 |
| NO304795B1 (no) | 1999-02-15 |
| CZ289515B6 (cs) | 2002-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU217439B (hu) | Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HU217446B (hu) | Norepesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| JP3424978B2 (ja) | 単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤 | |
| HUT67522A (en) | Bile acid derivatives, process for producing them and pharmaceutical compositions containing them | |
| JP2642090B2 (ja) | 胆汁酸誘導体 | |
| KR100319562B1 (ko) | 담즙산유도체,이의제조방법및이를함유하는저지질혈증제 | |
| JP3237882B2 (ja) | 胆汁酸誘導体、その製法および医薬としてのこれらの化合物の使用 | |
| AU757366B2 (en) | Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism | |
| Miki et al. | Sulfonate analogues of chenodeoxycholic acid: metabolism of sodium 3 alpha, 7 alpha-dihydroxy-25-homo-5 beta-cholane-25-sulfonate and sodium 3 alpha, 7 alpha-dihydroxy-24-nor-5 beta-cholane-23-sulfonate in the hamster. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HMM4 | Cancellation of final prot. due to non-payment of fee |